Clinical Trials · NCT06851962
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
- Phase
- Phase 4
- Recruitment status
- Active Not Recruiting
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
- Enrollment
- 504
- Start date
- May 2025
- Locations
- 3 sites, Spain
- Primary endpoint
- Comparison of HbA1c ≤7% goal at Week 24 between Pharmacogenetic-Guided and Standard Treatment in Type 2 Diabetes